To authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical goods to contribute to the national security and public health of the United States, and for other purposes.
Summary
What This Bill Does
The bill creates congressional findings on medical supply chain vulnerabilities exposed by COVID-19: U.S, creates statement of purposes: improve medical supply chain resilience through trusted trade partners, enhance supply chain security for technology and IP, diversify supplier networks, eliminate trade barriers, expedite, and defines key terms: medical device (21 USC 321 device for human use), medical good (device, pharmaceutical, or input), pharmaceutical good (21 USC 321 drug for human use), medical supply chain, trusted trade partner. It relies on trade restrictions, compliance mandates, definition changes, and tariffs. The main policy areas are Healthcare.
Who Benefits and How
Medical goods importers from trusted partner countries could see lower costs, Allied countries medical goods manufacturers could gain revenue opportunities, and Congressional trade committees would be affected.
Who Bears the Burden and How
United States Trade Representative would take on compliance duties, Trusted trade partner countries would take on compliance duties, and Countries excluded from trusted partner status could face higher barriers.
Key Provisions
- Creates congressional findings on medical supply chain vulnerabilities exposed by COVID-19: U.S.
- Creates statement of purposes: improve medical supply chain resilience through trusted trade partners, enhance supply chain security for technology and IP, diversify supplier networks, eliminate trade barriers, expedite...
- Defines key terms: medical device (21 USC 321 device for human use), medical good (device, pharmaceutical, or input), pharmaceutical good (21 USC 321 drug for human use), medical supply chain, trusted trade partner...
- Imposes grants President authority to negotiate, enter, and enforce trusted trade partner agreements for reciprocal elimination of duties on medical goods when it serves national security and public health.
- Establishes Congressional oversight framework: 60-day advance notice before negotiations, USTR consultation with committees, mandatory reports before entering agreements, ITC advice requirement, 60-day consultation...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates congressional findings on medical supply chain vulnerabilities exposed by COVID-19: U.S, creates statement of purposes: improve medical supply chain resilience through trusted trade partners, enhance supply chain security for technology and IP, diversify supplier networks, eliminate trade barriers, expedite, and defines key terms: medical device (21 USC 321 device for human use), medical good (device, pharmaceutical, or input), pharmaceutical good (21 USC 321 drug for human use), medical supply chain, trusted trade partner.
Key Policy Areas
Healthcare
Primary Purpose
The bill creates congressional findings on medical supply chain vulnerabilities exposed by COVID-19: U.S, creates statement of purposes: improve medical supply chain resilience through trusted trade partners, enhance supply chain security for technology and IP, diversify supplier networks, eliminate trade barriers, expedite, and defines key terms: medical device (21 USC 321 device for human use), medical good (device, pharmaceutical, or input), pharmaceutical good (21 USC 321 drug for human use), medical supply chain, trusted trade partner.
Policy Domains
Sections 2-3 - Findings and Purposes
Identified Gains
- Medical goods importers from trusted partner countries
- Allied countries medical goods manufacturers
- Congressional trade committees
- U.S. medical goods supply chain
- U.S. healthcare providers
Identified Costs
- United States Trade Representative
- Trusted trade partner countries
- Countries excluded from trusted partner status
Sponsors
Legislative Progress
IntroducedMr. Tillis (for himself, Mr. Coons, Mr. Cornyn, and Mr. …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Allied countries medical goods manufacturers, Domestic medical goods manufacturers, Medical device manufacturers
Positive-direction: Allied countries medical goods manufacturers, Medical goods importers from trusted partner countries, U.S. healthcare providers, U.S. medical goods supply chain
Negative-direction: Domestic medical goods manufacturers
Congressional trade committees, United States Trade Representative
Positive-direction: Congressional trade committees
Negative-direction: United States Trade Representative
Countries excluded from trusted partner status, Trusted trade partner countries
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_president"
- → President of the United States
- "trade_representative"
- → United States Trade Representative
- "itc"
- → International Trade Commission
- "the_president"
- → President
- "trade_representative"
- → USTR
- "the_president"
- → President
- "trade_representative"
- → USTR
Key Definitions
Terms defined in this bill
Any foreign country or territory, including overseas dependent territories, or Trust Territory of Pacific Islands
A device as defined under 21 USC 321 intended for use in humans
Any medical device, pharmaceutical good, or input for such a device or good
A drug as defined under 21 USC 321 intended for use in humans
Any country that has entered into an agreement with the United States under section 5
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology